SCM Lifescience kicks off anti-hair loss product exports to SE Asia

South Korea’s stem cell tech company SCM Lifescience on Wednesday said it has started full-scale exports to Southeast Asia of its hair loss care brand Iroro.

The first shipment to leave Sunday comprises 60,000 units of four products for the company's Malaysian partner Duopharma Consumer Healthcare, an affiliate of the public pharmaceutical company Duopharma Biotech Berhad.

Last year, both sides signed a supply contract for the four items including hair loss-mitigating shampoos for men and women containing the patented stem cell protein CXCL1, treatment and serum. 

SCM Lifescience also received halal certification from the Korea Muslim Federation’s Halal Certification Committee for the four products.

SCM Lifescience has completed patent registration for CXCL1 in South Korea, the US, China, Europe, Japan and Russia.

“This is Duopharma’s first distribution and sale in Malaysia, Singapore, Brunei and the Philippines,” an SCM Lifescience source said. “Though not yet ready for mass supply, Southeast Asia has high demand for hair care products and its supply capacity is expected to gradually expand.”

SCM Lifescience will use this inaugural export as an opportunity to enter the global dermo-cosmetics market. One forthcoming item is its cell culture fluid-containing Iroro Newborn AD Cream, which has human stem cell conditioned media used to culture cells in the company's development of treatments for moderate to severe atopic dermatitis.

Write to In-Hyuk Park at hyuk@hankyung.com